Literature DB >> 9259429

Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice.

G D Levy1, S J Munz, J Paschal, H B Cohen, K J Pince, T Peterson.   

Abstract

OBJECTIVE: To define the true risk of hydroxychloroquine (HCQ) retinal toxicity by studying the largest single group yet evaluated.
METHODS: Retrospective chart review of all patients in the Kaiser Permanente Medical Care Program, Southern California Region, who had HCQ prescriptions filled from 1991 through 1993 (1,556 patients in 11 medical centers). Of 1,207 charts of patients who took HCQ and had documented ophthalmologic examinations, initial screening identified 21 charts (1.7%) that indicated possible HCQ toxicity.
RESULTS: We identified 1 patient with definite toxicity (1 of 1,207; 0.08%) and 5 other patients with indeterminate but probable toxicity (5 of 1,207; 0.4%). The incidence of definite HCQ retinal toxicity in patients treated with HCQ at <6.5 mg/kg/day was 0.
CONCLUSION: In HCQ-treated patients whose renal function is normal, routine ophthalmic screening is not indicated if the daily dosage is <6.5 mg/kg. In patients whose daily dosage is >6.5 mg/kg or who have taken HCQ continuously for > 10 years, annual screening may be appropriate.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9259429     DOI: 10.1002/art.1780400817

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  47 in total

Review 1.  Autophagy inhibitors.

Authors:  Benoit Pasquier
Journal:  Cell Mol Life Sci       Date:  2015-12-11       Impact factor: 9.261

Review 2.  The role of antimalarial agents in the treatment of SLE and lupus nephritis.

Authors:  Senq-J Lee; Earl Silverman; Joanne M Bargman
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

3.  Ophthaproblem. Chloroquine or hydroxychloroquine retinopathy.

Authors:  Wei Liu; Sanjay Sharma
Journal:  Can Fam Physician       Date:  2005-05       Impact factor: 3.275

4.  Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy.

Authors:  Timothy Y Y Lai; Jasmine W S Ngai; Wai-Man Chan; Dennis S C Lam
Journal:  Doc Ophthalmol       Date:  2006-06-28       Impact factor: 2.379

5.  Long-term effectiveness of antimalarial drugs in rheumatic diseases.

Authors:  J A Aviña-Zubieta; G Galindo-Rodriguez; S Newman; M E Suarez-Almazor; A S Russell
Journal:  Ann Rheum Dis       Date:  1998-10       Impact factor: 19.103

6.  Screening for hydroxychloroquine retinopathy. Screening should be selective.

Authors:  K May; T Metcalf; A Gough
Journal:  BMJ       Date:  1998-11-14

Review 7.  [Progressive maculopathy despite discontinuation of chloroquine treatment-multimodal imaging and review of the literature].

Authors:  A Rickmann; S Al-Nawaiseh; L Ramirez; S Röhrig; M Ladewig; P Szurman; G Szurman
Journal:  Ophthalmologe       Date:  2020-09       Impact factor: 1.059

Review 8.  Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge.

Authors:  Y Ioannou; D A Isenberg
Journal:  Postgrad Med J       Date:  2002-10       Impact factor: 2.401

9.  Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria.

Authors:  R R Winkelmann; Grace K Kim; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2013-01

10.  Hydroxychloroquine retinopathy screening.

Authors:  A E Semmer; M S Lee; A R Harrison; T W Olsen
Journal:  Br J Ophthalmol       Date:  2008-10-01       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.